The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

One such molecule is the CD40L, which engages CD40 on dendritic and B cells of the immune system, enabling T cells to become activated as a result. Rodent studies using coreceptor blockade with ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

Further support for this concept comes from animal models of autoimmunity and transplantation, where treatments based on costimulation blockade, in particular CD40 ligand (CD40L)-specific ...

Background Soluble CD40 ligand (sCD40L) is a powerful marker of cardiovascular risk. Exercise is known to decrease cardiovascular risk, but the impact of ultra-endurance exercise on sCD40L responses ...

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...

UCB and Biogen’s drug dapirolizumab pegol has met the primary endpoint of improvement in disease activity in lupus patients.

Eledon Pharmaceuticals (ELDN) Company Description: Eledon Pharmaceuticals, Inc. (Nasdaq:ELDN) is an immunology-focused biotechnology company utilizing its experience in the CD40/CD40L costimulatory ...

AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally ...